Decision Regret Following Yonsei-Point Botulinum Toxin for Gummy Smile

This study evaluates patient-reported decision regret in adult patients who previously received standardized Botulinum Toxin Type A (BoNT-A) injection at the Yonsei Point for excessive gingival display (gummy smile). While BoNT-A provides predictable millimetric reduction in gingival exposure, subjective patient satisfaction and cognitive-emotional remorse remain under-investigated in periodontal plastic literature. Eligible patients will be identified from hospital treatment records at Cairo University Faculty of Dentistry. Patient-reported decision regret will be measured at 3 months post-treatment using the Ottawa Decision Regret Scale (ODRS). Archived clinical and photogrammetric smile records will also be audited to evaluate gingival display reduction in millimeters.

Inclusion Criteria:- Adult patients aged 18 years or older. * Patients diagnosed with excessive gingival display (\>=3 mm exposure during maximum smile) due to upper lip hyperactivity. * Patients who previously received standardized Botulinum Toxin Type A (BoNT-A) injection at the Yonsei point. * Presence of complete baseline and 3-month post-treatment clinical and photographic records. Exclusion Criteria: * Patients with vertical maxillary excess (VME) or altered passive eruption as the primary etiology of gummy smile. * Patients who underwent concomitant periodontal plastic surgery or lip repositioning. * Patients with a history of neuromuscular disorders (e.g., Myasthenia Gravis). * Pregnant or lactating females at the time of treatment.